1. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?
    Itsuro Kazama, 2020, DD&T CrossRef
  2. Persistence of COVID-19 Symptoms after Recovery in Mexican Population
    Carlos E. Galván-Tejada et al, 2020, IJERPH CrossRef
    Khushali Jain et al, 2020, ijsr CrossRef
  4. S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19
    S. Kluge et al, 2021, Pneumologie CrossRef
  5. Tracking the time course of pathological patterns of lung injury in severe COVID-19
    Thais Mauad et al, 2021, Respir Res CrossRef
  6. Healing after COVID-19: are survivors at risk for pulmonary fibrosis?
    Lindsay T. McDonald, 2021, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
  7. COVID-19: Direct and Indirect Mechanisms of Statins
    Agnieszka Pawlos et al, 2021, IJMS CrossRef
  8. The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis
    Paschalis Ntolios et al, 2021, Biomedicines CrossRef
  9. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
    Elia Bari et al, 2021, Cells CrossRef
  10. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study
    Álvaro Romero-Duarte et al, 2021, BMC Med CrossRef
  11. Dynamic role of LMW-hyaluronan fragments and Toll-like receptors 2,4 in progression of bleomycin induced lung parenchymal injury to fibrosis
    Apoorva Pandey et al, 2021, Egypt J Bronchol CrossRef
  12. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic
    Shiva Rattan Ambardar et al, 2021, JCM CrossRef
  13. Overview of the pathogenesis of COVID‑19 (Review)
    Chao Li et al, 2021, Exp Ther Med CrossRef
  14. Lung Fibrosis after COVID-19: Treatment Prospects
    Evgeny Bazdyrev et al, 2021, Pharmaceuticals CrossRef
  15. Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
    José M. Serra López-Matencio et al, 2021, Pharmaceuticals CrossRef
  16. mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
    Simona Granata et al, 2021, Front. Pharmacol. CrossRef
  17. Long‑term effects of COVID‑19 in sickle cell disease: A case report
    Ricardo Alberca et al, 2021, World Acad Sci J CrossRef
  18. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells
    Ioanna Nikitopoulou et al, 2021, IJMS CrossRef
  19. Cell Properties of Lung Tissue-Resident Macrophages Propagated by Co-Culture with Lung Fibroblastic Cells from C57BL/6 and BALB/c Mice
    Mayu Tsurutani et al, 2021, Biomedicines CrossRef
  20. Pathogenetic bases of the use of antifibrotic therapy with Bovhyaluronidazum azoximerum in patients with new coronavirus infection COVID-19
    O. A. Chernyavskaya et al, 2021, Medicinskij sovet CrossRef
  21. Advances and challenges in Nintedanib drug delivery
    Varalakshmi Velagacherla et al, 2021, Expert Opinion on Drug Delivery CrossRef
  22. Pulmonary complications due to COVID-19 – a literature review
    Anna Maria Romaszko-Wojtowicz et al, 2021, Pol. Ann. Med. CrossRef
  23. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
    Konstantinos Ntatsoulis et al, 2021, Front. Immunol. CrossRef
  24. SARS-CoV-2 diagnosis: a single-centre experience
    Ion Maruntelu et al, 2021, JMedLife CrossRef
  25. Alveolar Regeneration in COVID-19 Patients: A Network Perspective
    Shishir K. Gupta et al, 2021, IJMS CrossRef
  26. Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections
    Georg von Massow et al, 2021, Front. Immunol. CrossRef
  27. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors
    Andrea Vianello et al, 2021 CrossRef
  28. Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics
    Eleonore Fröhlich, 2021, Biomedicines CrossRef
  29. Temporal Patterns of COVID-19-Associated Pulmonary Pathology: An Autopsy Study
    George S Stoyanov et al, 2021 CrossRef
  30. The “Elastic Perspective” of SARS-CoV-2 Infection and the Role of Intrinsic and Extrinsic Factors
    Federica Boraldi et al, 2022, IJMS CrossRef
  31. Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2/STAT3 signaling
    Xiaolan You et al, 2022, Aging CrossRef
  32. Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis
    Mahbub Hasan et al, 2022, Molecules CrossRef
  33. Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection
    Jian Li et al, 2022, Molecules CrossRef
  34. Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications
    Ankita Sood et al, 2022, Inflammopharmacol CrossRef
  35. Impact of the COVID-19 Pandemic on Trends in Cardiothoracic Imaging
    Kathleen M. Capaccione et al, 2022, Radiology Research and Practice CrossRef
  36. Respiratorische Viren, COVID und Lungenfibrose – alles wie beim ARDS oder doch anders?
    Fotios Drakopanagiotakis et al, 2021, Kompass Pneumol CrossRef
  37. The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline.
    Jeffrey D Pyne et al, 2021, Neurodegener Dis CrossRef
  38. Radiologically suspected COVID‑19‑associated organizing pneumonia responding well to corticosteroids: A report of two cases and a review of the literature
    Christos Siafarikas et al, 2022, Exp Ther Med CrossRef
  39. PTPα promotes fibroproliferative responses after acute lung injury.
    Yael Aschner et al, 2022, Am J Physiol Lung Cell Mol Physiol CrossRef
  40. The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
    Pedro Silva Cunha et al, 2022, Front. Cardiovasc. Med. CrossRef
  41. TRPM7 restrains plasmin activity and promotes transforming growth factor-β1 signaling in primary human lung fibroblasts
    Sarah Zeitlmayr et al, 2022, Arch Toxicol CrossRef
  42. Dual inhibition of CB 1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19
    Resat Cinar et al, 2022, British J Pharmacology CrossRef
  43. β-Carboline Alkaloids From the Deep-Sea Fungus Trichoderma sp. MCCC 3A01244 as a New Type of Anti-pulmonary Fibrosis Agent That Inhibits TGF-β/Smad Signaling Pathway
    Meng-Jiao Hao et al, 2022, Front. Microbiol. CrossRef
  44. Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease
    Naveen Dutt et al, 2022 CrossRef
  45. Interstitial Lung Fibrosis Following COVID-19 Pneumonia
    Mihai Lazar et al, 2022, Diagnostics CrossRef
  46. Lung transplantation in patients with COVID-19- the early national experience
    Isabella Florissi et al, 2022, Seminars in Thoracic and Cardiovascular Surgery CrossRef
  47. Irreversible Lung Transformation Resulting from Damage In COVID-19 — Discourses and Examples of CT Images
    A. S. Vinokurov et al, 2022, Arhivʺ vnutrennej mediciny CrossRef
  48. Prospects of Hyaluronidase Therapy in Novel COVID-19 Infection with Damage to Lungs
    Aleksandra V. Solov’yeva et al, 2022, I.P. Pavlov Russian Medical Biological Herald CrossRef
  49. SARS-CoV-2 Associated Pulmonary Pathology
    George S. Stoyanov et al, 2022, Encyclopedia CrossRef
  50. The effect of Pirfenidone on pulmonary function parameters in post recovery COVID-19 patients with pulmonary fibrosis compared to placebo in a Government Medical College, West Bengal
    Tanmoy Banerjee et al, 2022, Biomedicine CrossRef
  51. Materdicine and Medmaterial
    Hui HUANG et al, 2022, Journal of Inorganic Materials CrossRef
  52. An interpretable deep learning workflow for discovering subvisual abnormalities in CT scans of COVID-19 inpatients and survivors
    Longxi Zhou et al, 2022, Nat Mach Intell CrossRef
  53. Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges
    Rudolf K. F. Oliveira et al, 2022, Front. Med. CrossRef
  54. null
    Sivakumar Nagaraju et al, 2024 CrossRef
  55. A case of successful treatment of diffuse post-coronavirus pulmonary fibrosis with pirfenidone
    Svitlana Bychkova et al, 2023, Pol. Ann. Med. CrossRef
  56. Deciphering the age-dependent changes of pulmonary fibroblasts in mice by single-cell transcriptomics
    Rundong Wu et al, 2023, Front. Cell Dev. Biol. CrossRef